Unknown

Dataset Information

0

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay.


ABSTRACT: Phosphorylation of tau at Ser (396, 404) (p-tau396,404) is one of the earliest phosphorylation events, and plasma p-tau396,404 level appears to be a potentially promising biomarker of Alzheimer's disease (AD). The low abundance and easy degradation of p-tau in the plasma make the lateral flow assay (LFA) a suitable choice for point-of-care detection of plasma p-tau396,404 levels. Herein, based on our screening of a pair of p-tau396,404-specific antibodies, we developed a colorimetric and surface-enhanced Raman scattering (SERS) dual-readout LFA for the rapid, highly sensitive, and robust detection of plasma p-tau396,404 levels. This LFA realized a detection limit of 60 pg/mL by the naked eye or 3.8 pg/mL by SERS without cross-reacting with other tau species. More importantly, LFA rapidly and accurately differentiated AD patients from healthy controls, suggesting that it has the potential for clinical point-of-care application in AD diagnosis. This dual-readout LFA has the advantages of simple operation, rapid, and ultra-sensitive detection, providing a new way for early AD diagnosis and intervention, especially in primary and community AD screening.

Electronic supplementary material

Supplementary material (characterization of AuNPs and 4-MBA@AuNP probe; the optimal 4-MBA load for AuNPs; the optimal K2CO3 volumes for 4-MBA@AuNP-3G5 conjugates; the optimal 3G5 load for 4-MBA@AuNP conjugates; effect of NaCl concentration on 4-MBA@AuNP-3G5 stability; the linear curve of T-line color and SERS intensity versus different p-tau396,404 concentrations; the comparison of colorimetric-based LFA test results and the diagnosis results; Raman intensities and antibody activity of 4-MBA@AuNP-3G5 before and after storage; colorimetric intensity of dual-readout LFA detecting different concentrations of p-tau396,404 protein; sequence of synthesized peptides used in this study; information of the participants in this study; the information of antibodies used in this study) is available in the online version of this article at 10.1007/s12274-022-5354-4.

SUBMITTER: Zhang L 

PROVIDER: S-EPMC9971675 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay.

Zhang Liding L   Su Ying Y   Liang Xiaohan X   Cao Kai K   Luo Qingming Q   Luo Haiming H  

Nano research 20230228 5


Phosphorylation of tau at Ser (396, 404) (p-tau<sup>396,404</sup>) is one of the earliest phosphorylation events, and plasma p-tau<sup>396,404</sup> level appears to be a potentially promising biomarker of Alzheimer's disease (AD). The low abundance and easy degradation of p-tau in the plasma make the lateral flow assay (LFA) a suitable choice for point-of-care detection of plasma p-tau<sup>396,404</sup> levels. Herein, based on our screening of a pair of p-tau<sup>396,404</sup>-specific antibod  ...[more]

Similar Datasets

| S-EPMC11090086 | biostudies-literature
| S-EPMC4720322 | biostudies-literature
| S-EPMC6695641 | biostudies-literature
| S-EPMC3842097 | biostudies-literature
| S-EPMC4985229 | biostudies-literature
| S-EPMC8097318 | biostudies-literature
| S-EPMC8711265 | biostudies-literature
| S-EPMC9556598 | biostudies-literature
| S-EPMC3989393 | biostudies-literature
| S-EPMC9034092 | biostudies-literature